SHR0302

TargetMol
Product Code: TAR-T9195
Supplier: TargetMol
CodeSizePrice
TAR-T9195-1mg1mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9195-2mg2mg£342.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9195-5mg5mg£535.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9195-1mL1 mL * 10 mM (in DMSO)£603.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9195-10mg10mg£740.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9195-25mg25mg£1,091.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9195-50mg50mg£1,428.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9195-100mg100mg£1,910.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
SHR0302 is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 420 times for Tyk2).
CAS:
1445987-21-2
Formula:
C18H22N8O2S
Molecular Weight:
414.49
Pathway:
Stem Cells; Apoptosis; Chromatin/Epigenetic; Angiogenesis; JAK/STAT signaling
Purity:
0.98
SMILES:
COc1nsc(NC(=O)N2C[C@@H]3CC(C[C@@H]3C2)N(C)c2ncnc3[nH]ccc23)n1
Target:
Apoptosis; JAK

References

Gu Y J , Sun W Y , Zhang S , et al. Targeted blockade of JAK/STAT3 signaling inhibits proliferation, migration and collagen production as well as inducing the apoptosis of hepatic stellate cells[J]. International Journal of Molecular Medicine, 2016. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total Bcells[J]. Joint Bone Spine Revue Du Rhumatisme, 2016:525-532.